Jim Simons’s Nuvectis Pharma NVCT Stock Holding History

Jim Simons’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42,800	Closed	-$258K	–	3593
2025 Q3	$258K	Sell	42,800 -200	-0.5%	-$1.38K	﹤0.01%	3063
2025 Q2	$321K	Buy	+43,000	New	+$390K	﹤0.01%	3019
2024 Q4	–	Sell	-15,800	Closed	-$99.4K	–	3797
2024 Q3	$99.4K	Sell	15,800 -58,700	-79%	-$386K	﹤0.01%	3259
2024 Q2	$472K	Buy	74,500 +12,800	+21%	+$87K	﹤0.01%	2713
2024 Q1	$506K	Buy	61,700 +9,900	+19%	+$84.2K	﹤0.01%	2860
2023 Q4	$432K	Buy	51,800 +26,400	+104%	+$235K	﹤0.01%	2845
2023 Q3	$327K	Sell	25,400 -11,000	-30%	-$159K	﹤0.01%	2890
2023 Q2	$581K	Buy	+36,400	New	+$581K	﹤0.01%	2789

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Jim Simons's NVCT Position: Q4 2025 in Review

Jim Simons sold out of Nuvectis Pharma (NVCT) in Q4 2025, closing a stake of 42,800 shares — an estimated $258K sold.

Jim Simons first reported a position in NVCT in Q2 2023 and held it in 8 quarters. The position peaked at $581K in Q2 2023. 48 funds tracked by Wall St. Rank hold NVCT as of Q4 2025.

Jim Simons reported no remaining Nuvectis Pharma position as of Q4 2025 after selling out during the quarter.
Jim Simons sold 42,800 Nuvectis Pharma shares in Q4 2025, an estimated $258K.
Jim Simons first reported a position in Nuvectis Pharma in Q2 2023 and held it in 8 quarters.
Jim Simons's Nuvectis Pharma position peaked at $581K in Q2 2023.
48 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.